Ternary Therapeutics Raises £3.6 Million in Seed Funding
Ternary Therapeutics, a London-based biotech startup, has successfully raised £3.6 million in a seed funding round. The company, founded in 2024, is at the forefront of drug discovery, focusing on the development of molecular glues — a new class of drugs that can target previously 'undruggable' proteins. Ternary combines machine learning and molecular dynamics simulations with AI-augmented drug discovery to engineer these molecules systematically rather than relying on chance discoveries.
Investors and Funding Details
The seed funding round was led by the venture capital firm daphni, with additional investments from Pace Ventures, i&i Biotech Fund, and the UK Innovation & Science Seed Fund. This financial backing is expected to accelerate Ternary's efforts in revolutionizing the drug discovery process.
Innovative Drug Discovery Approach
Ternary Therapeutics aims to tackle some of the most challenging aspects of drug discovery by creating an AI platform that designs molecular glues. These drugs are unique in their ability to bring proteins together, targeting areas that have long been considered difficult to influence with traditional pharmaceuticals.
"Molecular glues have delivered some of the most exciting breakthroughs in drug discovery over the past decade," said Chris Tame, Founder and CEO of Ternary Therapeutics. "Our platform is designed to change that by combining physics-informed AI with rapid experimental validation to engineer these molecules intentionally and at scale."
Strategic Use of Funds
The newly acquired funds will primarily be used to enhance Ternary's AI platform, enabling more precise predictions and faster iterations in drug design. The company plans to integrate more advanced machine learning models and expand its laboratory testing capabilities.
Looking Ahead
With this substantial seed investment, Ternary Therapeutics is well-positioned to make significant strides in AI-driven drug discovery. The company’s approach could potentially lead to breakthroughs in treating diseases that have so far been difficult to address with existing pharmaceuticals.
This funding marks a critical step for Ternary as it continues to develop its innovative platform, aiming to transform the landscape of molecular glue drug discovery.